DCF Valuation Models for Thermo Fisher Scientific Indicate Fairly Valued Stock, with Mixed Signals from Multiple Approaches

A recent analysis published on June 1, 2026, by GuruFocus reveals that the intrinsic value per share of Thermo Fisher Scientific is approximately $477.60, according to an earnings-based discounted cash flow model.

With the current share price around $492.51, the model suggests the stock is trading within a reasonable valuation range.



The GuruFocus analysis utilized a two-stage DCF model, incorporating key assumptions such as a 10-year growth rate of 13.8%, a discount rate of 11%, and a terminal growth rate of 4%.

Based on these inputs, the model calculated a value of $266.29 per share for the growth stage and $211.31 per share for the terminal stage, resulting in the final intrinsic value of $477.60 per share.

The analysis notes that, given the proximity of the stock price to this valuation level, the shares are considered "fairly valued" at current levels, with a margin of safety of -3.1%.



It is important to highlight that the GuruFocus analysis incorporated three distinct valuation models, which together present a complex picture.

The DCF earnings model indicates fair valuation, while a DCF free cash flow model yields a significantly lower intrinsic value of $333.59 per share, suggesting the stock may be moderately overvalued with a margin of safety of -47.6%.

Additionally, the GF Value metric is set at $579.58 per share.



Thermo Fisher has recently undertaken several significant strategic moves.

The company reported first-quarter results that exceeded expectations, with revenue reaching $11.01 billion and adjusted earnings per share of $5.44.

Furthermore, the company has entered into an agreement to sell its microbiology business to the European private equity firm Astorg for approximately $1.075 billion, with the transaction expected to close in the second half of 2026.



The valuation discrepancies among the different models, combined with recent complex corporate developments, suggest the stock is in a nuanced position.

While the earnings-based DCF valuation points to a reasonable price, other metrics indicate potential risks for investors.